Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 3/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16217771 | 1.00 | LMNA (0.67) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL20828068 | 1.00 | LMNA (0.67) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL17448301 | 1.00 | LMNA (0.67) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23069355 | 0.99 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL31400149 | 0.99 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL27417572 | 0.99 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL27417540 | 0.97 | LMNA (0.68) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL27417631 | 0.94 | LMNA (0.70) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL18073843 | 0.93 | LMNA (0.57) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL27417486 | 0.90 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218023-A1 | CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS | MICROBIO (SHANGHAI) CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-01-13 | — | — | US | disclosed |
| EP-3234132-B1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202855-A1 | POLYNUCLEOTIDE CONSTRUCTS | SIRIUS THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190194655-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | BRADSHAW CURT W (US) | 2019-06-27 | — | — | US | disclosed |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2016100401-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218023-A1 | CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS | GALNT1, CSGALNACT1, GALNT2 | LMNA 1541/4885KMT2A 3597/4885POLB 4657/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | LMNA 885/4885KMT2A 3611/4885POLB 4492/4885 |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | LMNA 412/4885KMT2A 3810/4885POLB 157/4885 |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | LMNA 3266/4885KMT2A 2560/4885POLB 1646/4885 |
| US-20190202855-A1 | POLYNUCLEOTIDE CONSTRUCTS | PHAX, CPSF6, RNGTT | LMNA 1084/4885KMT2A 3891/4885POLB 101/4885 |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | LMNA 528/4885KMT2A 2367/4885POLB 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.